Pressurized PPV 23GA Vitrectomy in Complicated Diabetic Tractional Retinal Detachment

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2007 by Asociación para Evitar la Ceguera en México.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Asociación para Evitar la Ceguera en México
ClinicalTrials.gov Identifier:
NCT00404209
First received: June 30, 2006
Last updated: November 29, 2007
Last verified: November 2007
  Purpose

To investigate the feasibility and advantages of using pressurized perfluorocarbon liquid (PCL) perfusion to remove vitreous during suction-cutting 23 GA vitrectomy using a dual, dynamic drive (3D)technology, in complicated retinal detachment surgeries.


Condition Intervention Phase
Retinal Detachment
Procedure: Vitrectomy
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Pressurized Perfluorocarbon Perfused 23 GA Vitrectomy in Complicated Diabetic Retinal Detachment

Resource links provided by NLM:


Further study details as provided by Asociación para Evitar la Ceguera en México:

Primary Outcome Measures:
  • Perfluorocarbon liquids consumption [ Time Frame: two months ] [ Designated as safety issue: No ]

Estimated Enrollment: 10
Study Start Date: March 2007
Estimated Study Completion Date: February 2008
Intervention Details:
    Procedure: Vitrectomy
    pressurized 23GA vitrectomy with a 3D system
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Complicated retinal detachment with no more than 6months of evolution

Exclusion Criteria:

  • Retinal detachments of more than 6 months of evolution No light perception
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00404209

Contacts
Contact: Hugo Quiroz-Mercado, MD 5255 10841400 ext 1171 retinamex@yahoo.com

Locations
Mexico
Asociación para Evitar la Ceguera en México, Hospital "Luis Sánchez Bulnes" Recruiting
Mexico City, Mexico DF, Mexico, 04030
Contact: Hugo Quiroz-Mercado, MD    5255 10841400 ext 1171    retinamex@yahoo.com   
Sub-Investigator: Maria A Martinez-Castellanos, MD         
Sub-Investigator: Gerardo Garcia-Aguirre, MD         
Sub-Investigator: Orlando Ustariz-Gonzalez, MD         
Sub-Investigator: Jose L Guerrero-Naranjo, MD         
Sub-Investigator: Jans Fromow-Guerra, MD         
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Investigators
Principal Investigator: Hugo Quiroz-Mercado, MD Asociación para Evitar la Ceguera en Mexico, Hospital "Luis Sanchez Bulnes"
Principal Investigator: Raul Velez-Montoya, MD Asociación para Evitar la Ceguera en México
  More Information

No publications provided

Responsible Party: Hugo Quiroz-Mercado, Asociacion para evitar la ceguera en Mexico
ClinicalTrials.gov Identifier: NCT00404209     History of Changes
Other Study ID Numbers: APEC-008
Study First Received: June 30, 2006
Last Updated: November 29, 2007
Health Authority: Mexico: Ministry of Health

Additional relevant MeSH terms:
Retinal Detachment
Dissociative Disorders
Retinal Diseases
Eye Diseases
Mental Disorders

ClinicalTrials.gov processed this record on July 22, 2014